S EVERAL STUDIES have reported that the tetracycline antibiotics minocycline and doxycycline (Agrawal et al., 2011; McIver etal., 2012) are effective in reducing alcohol consumption. Notably, others have shown that alcohol consumption can affect several components of the neuroimmune system (Blednov et al., 2012; Montesinos et al., 2016) . In this commentary, Syapin and colleagues (2016) explore how tigecycline outperforms doxycycline and minocycline in reducing binge alcohol drinking in the dark (DID). In agreement with their findings, Bergeson and colleagues (2016b) further elucidate how tigecycline can reliably reduce alcohol dependence in a combined chronic intermittent ethanol (CIE) vapor and 2-bottle choice alcohol consumption model (Fig. 1) .
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The tetracycline class of broad-spectrum antibiotics is effective against Gram-positive and Gram-negative bacterial microorganisms. This class of compounds allosterically inhibits the association between aminoacyl tRNA and the 30S and 50S ribosomal subunits, resulting in derailment of transcriptional activity (Griffin et al., 2011) . While this class of antibiotics has seen decreased use as a result of microorganism resistance, the use of these compounds for their nonantimicrobial properties (reactive oxygen species [ROS] scavenging, inhibition of extracellular matrix proteolysis by matrix-metalloproteinases [MMPs] , anti-apoptotic neuroprotection, and inhibition of pro-inflammatory cytokines) have opened new avenues of investigation (Griffin et al., 2011) . In this regard, the dose-response study of tetracycline derivatives by Syapin and colleagues (2016) provides timely information and identified tigecycline as the best candidate. Although tigecycline appears to be the least efficacious in reducing alcohol consumption, its advantages lie in that it does not alter water intake or induce toxicity, a shared effect of doxycycline and minocycline. The evidence for reduction in male and female DID alcohol consumption by semi-synthetic tetracyclines provided by Syapin and colleagues (2016) is further strengthened in a second investigation by Bergeson and colleagues (2016b) , which specifically focuses on the ability of tigecycline to significantly dampen alcohol dependence in a combined CIE vapor and 2-bottle choice alcohol consumption model. In this study, Bergeson and colleagues show that tigecycline was efficacious in reducing alcohol consumption in both male and female C57BL/6J mice, without affecting water consumption. However, it is unclear from this study whether tigecycline is targeting systems directly altered by chronic alcohol intake or whether these results are off-target effects common to this class of compounds. Tigecycline lowered alcohol intake in dependent (alcohol vapor-exposed) and nondependent (air-exposed) mice, albeit without alcohol drinking differences between these 2 cohorts. Therefore, these results should be strengthened by future studies that test tigecycline on rodent models (i.e., high-alcohol-preferring P-rat or HAD1 rat model) known for their inherent high baseline of alcohol consumption (Bell et al., 2015) . Taken together, Syapin and colleagues (2016) and Bergeson and colleagues (2016b) indicate that tigecycline shows significant efficacy in reducing binge alcohol intake as well as alcohol consumption in alcohol-dependent male and female mice.
The results of these studies raise several questions in regard to how these compounds reduce alcohol intake. Although the authors do not show mechanistic evidence, they highlight the importance of a chemical modification at R6 0 , where substitution of -OH for -H may be an important determinant of the nonantimicrobial properties of minocycline and tigecycline. Therefore, we may speculate that this modification on tigecycline (or similar modifications on other tetracycline derivatives) may be an essential factor in the ability for this class of drug to disrupt MMP-mediated priming of microglia into reactivity or facilitation of peripheral monocyte infiltration across the blood-brain barrier (BBB). Thus, tigecycline may share minocycline's ability to inhibit antigen presentation and extravasation into the BBB by circulating peripheral T cells (Brundula et al., 2002; Kalish and Koujak, 2004) . Moreover, tigecycline may have the ability to regulate alcohol-induced cytokine "mini-storms" (i.e., release of TNF-a, IL-1b, and others cytokines/chemokines) that may form during presence of high levels of alcohol in brain (Crews and Vetreno, 2016; Lee and Kim, 2014) . Indeed, this has been a mechanism reported for tetracycline derivatives in relation to neuroinflammation caused by brain injury, epilepsys, and neurodegeneration (da Fonseca et al., 2014) . While we propose potential mechanisms of action for tigecycline, we should emphasize that the 4 companion studies by Bergeson and colleagues do not address whether alcohol is inducing a neuroinflammatory response in their subjects. Moreover, neuroimmune and behavioral response systems are bidirectional, as recent evidence indicates that activation of the reward system can boost immune responses (Ben-Shaanan et al., 2016) . Consequently, we stress careful consideration of the articles highlighted in this commentary when designing future studies aimed at elucidation of how tigecycline reduces alcohol consumption.
IS NEUROINFLAMMATION INVOLVED IN AUD?
Excessive long-term alcohol use exerts a physiologically detrimental effect on peripheral organs, including the pancreas, intestinal tract, and liver (Natarajan et al., 2015) . The mechanisms by which these damages occur vary and include increases in hepatic acetaldehyde production, increased ROS, fatty acid ethyl esters as well as release of the derived endotoxin lipopolysaccharide (LPS) (Natarajan et al., 2015) .
In particular, excessive alcohol consumption has been reported to damage intestinal epithelium resulting in leakage and systemic circulation of LPS, a molecule composed of the outer membrane of Gram-negative bacteria which has affinity for Toll-like receptors (TLRs) and in particular TLR-4 (Montesinos et al., 2016) . Importantly, the innate immune system engages an inflammatory response in many cell types including monocytes, macrophages, and central nervous system (CNS) microglia (Fernandez-Lizarbe et al., 2009 ). Consequently, NF-jB and AP-1 mediated transcriptional activity in microglia induce production and release of TNF-a and IL-1b (Crews and Vetreno, 2016) . Given alcohol's wellknown activation of LPS mediated innate immune responses, it is not surprising that recent investigations have revealed a role for microglia mediated neuroinflammation and neurodegeneration as a result of excessive alcohol exposure (Crews and Vetreno, 2016) . Although it is obvious that these discoveries advance our mechanistic understanding of how peripheral and CNS immunity contributes to AUD, it is of equal importance to harness this knowledge for novel therapeutic approaches.
TIGECYCLINE AND SEX DIFFERENCES IN PAIN RESPONSE
Alcohol has long been used to buffer against acute pain, which is simply a concentration of pro-inflammatory cytokines that are released in response to injury or infection. Paradoxically, uncontrolled chronic alcohol intake potentiates nociception in both males and females (Egli et al., 2012) . Given the beneficial anti-inflammatory effects of tetracyclines (Garrido-Mesa et al., 2013) , it is not surprising that Bergeson and colleagues (2016a) found tigecycline-promoted antinociception in male C57BL/6J mice. What was surprising were the sex-specific differences revealed by Bergeson and colleagues (Bergeson et al., 2016a) in responses to pain, as tigecycline seemed to potentiate nociception in female C57BL/6J mice. Sex-specific differences are well documented in terms of alcohol consumption. Interestingly, in rodent models of AUD, females display increased alcohol consumption relative to males, while the converse is observed in humans (Becker and Koob, 2016) . Therefore, the results of Bergeson and colleagues (2016a) are particularly interesting, given that in rodent models, females are reported to be less affected by pain from alcohol withdrawal severity (Becker and Koob, 2016) . One possible explanation for the paradoxical pro-nociception reported for females in Bergeson and colleagues (2016a) may include the differential effects of tigecycline on pain responses in male versus female mice, which could involve cell-specific immune-related responses. For example, sex-dependent developmental expression of TLR in microglia (Lenz et al., 2013) in addition to differences in T-cell activation in rodents has been reported (Sorge et al., 2015) . Notably, tetracyclines are known to affect the biochemical behavior of both microglia and T cells (Brundula et al., 2002; Garrido-Mesa et al., 2013; Kalish and Koujak, 2004) .
POTENTIAL MECHANISMS OF TIGECYCLINE ACTION ON AUD
As Syapin and colleagues (2016) and Bergeson and colleagues (2016b) point out in their discussion, follow-up mechanistic studies are indeed warranted to understand how this class of antibiotics function to reduce alcohol consumption. One mechanism worthy of consideration is the potential effect of tigecycline on the expression of genes that regulate synaptic levels of glutamate. We suggest this avenue of study based on evidence showing that the antibiotic ceftriaxone, a cephalosporin class of antibiotic, has been specifically implicated in alcohol seeking (Lee et al., 2013) , and in reducing alcohol withdrawal (AWD) symptomatology (Abulseoud et al., 2014) by altering expression of the excitatory amino acid glutamate transporter-2 (EAAT2; also known as GLT-1). Martinez and colleagues (2016) provide convincing evidence that tigecycline significantly reduces AWD severity, concluding that the convulsion reductions by tigecycline are yet another phenotype shared by the semi synthetic tetracyclines. Interestingly, there is evidence suggesting that by preventing microglial activation and subsequent release of pro-inflammatory cytokines, this class of compounds may protect against AWD-mediated convulsions (Wang et al., 2012) . More importantly, the authors point out that tigecycline may be used as an alternative to benzodiazepine treatment, as the latter is known to have high abuse potential. An additional benefit toward AUD therapy is tigecyclines long t 1/2 (between 40 and 60 hours), making it an ideal treatment. In terms of treatment compliance, minimizing administration of doses reported to induce nausea, vomiting, and gastrointestinal intolerance (200 to 300 mg/kg) should positively influence compliance in AUD patients (Muralidharan et al., 2005) . Optimizing route of administration in favor of maximizing oral bioavailability (as opposed to intravenous administration), in the doses reported to reliably reduce alcohol intake (50 to 100 mg/kg in the 4 companion studies), should also enhance compliance. Finally, careful monitoring for potential hepatotoxicity or renal complications is also warranted, given tigecyclines extensive volume of distribution and reportedly longer t 1/2 in noncentral compartments (bone, spleen, etc.) (Muralidharan et al., 2005) .
CONCLUSION
In conclusion, this group of companion papers provides new evidence for the ability of tigecycline, a semi synthetic tetracycline antibiotic, to reduce alcohol consumption, AWD symptomatology, and pain responses. Recent evidence implicates neuroimmune-neurocircuit feedback interactions in the regulation of behavior (Ben-Shaanan et al., 2016) . Thus, it is important to mechanistically determine how these seemingly disparate systems contribute to AUD by deciphering the role of tigecycline in immune responses. The preclinical studies discussed in this commentary highlight the novel repurposing of tigecycline to aid in reduction in several AUD-related phenotypes. However, before widespread clinical use of antibiotics to treat AUD can be entertained, careful consideration must be given to the antibiotic resistance crisis currently facing our healthcare system (Seputiene et al., 2010) .
